Tags

Type your tag names separated by a space and hit enter

Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis.
Vaccine. 2012 Mar 28; 30(15):2600-4.V

Abstract

Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip.

Authors+Show Affiliations

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. karin.leder@monash.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22234265

Citation

Leder, K, et al. "Aggregate Travel Vs. Single Trip Assessment: Arguments for Cumulative Risk Analysis." Vaccine, vol. 30, no. 15, 2012, pp. 2600-4.
Leder K, Chen LH, Wilson ME. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine. 2012;30(15):2600-4.
Leder, K., Chen, L. H., & Wilson, M. E. (2012). Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine, 30(15), 2600-4. https://doi.org/10.1016/j.vaccine.2011.12.133
Leder K, Chen LH, Wilson ME. Aggregate Travel Vs. Single Trip Assessment: Arguments for Cumulative Risk Analysis. Vaccine. 2012 Mar 28;30(15):2600-4. PubMed PMID: 22234265.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. AU - Leder,K, AU - Chen,L H, AU - Wilson,M E, Y1 - 2012/01/09/ PY - 2011/09/21/received PY - 2011/12/27/revised PY - 2011/12/28/accepted PY - 2012/1/12/entrez PY - 2012/1/12/pubmed PY - 2012/7/10/medline SP - 2600 EP - 4 JF - Vaccine JO - Vaccine VL - 30 IS - 15 N2 - Vaccine recommendations for travellers are based on individual risk assessments of multiple factors, most importantly the destination and duration of the impending trip. Many people undertake frequent trips, but existing WHO, CDC and national advisory board recommendations do not explicitly consider cumulative travel-associated risks. Given the period of protection provided by many vaccines, in particular rabies, hepatitis A, hepatitis B and yellow fever vaccines, an aggregate multi-trip risk assessment which views vaccines as an investment for future travel health may be more appropriate than separately evaluating the risks for each trip. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22234265/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)02094-9 DB - PRIME DP - Unbound Medicine ER -